ID   PC-9/BR
AC   CVCL_T015
SY   PC-9BR; PC-9/BRc1; PC-9BRc1
DR   cancercelllines; CVCL_T015
DR   Cosmic; 2015227
DR   Wikidata; Q54938480
RX   PubMed=21734175;
RX   PubMed=23733853;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:61390; Afatinib (BIBW-2992).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 05-10-23; Version: 18
//
RX   PubMed=21734175; DOI=10.1126/scitranslmed.3002356;
RA   Chmielecki J., Foo J., Oxnard G.R., Hutchinson K., Ohashi K.,
RA   Somwar R., Wang L., Amato K.R., Arcila M.E., Sos M.L., Socci N.D.,
RA   Viale A.J., de Stanchina E., Ginsberg M.S., Thomas R.K., Kris M.G.,
RA   Inoue A., Ladanyi M., Miller V.A., Michor F., Pao W.;
RT   "Optimization of dosing for EGFR-mutant non-small cell lung cancer
RT   with evolutionary cancer modeling.";
RL   Sci. Transl. Med. 3:90ra59.1-90ra59.10(2011).
//
RX   PubMed=23733853; DOI=10.1101/gr.152322.112;
RA   Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L.,
RA   Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.;
RT   "Next-generation sequencing of paired tyrosine kinase
RT   inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines
RT   identifies spectrum of DNA changes associated with drug resistance.";
RL   Genome Res. 23:1434-1445(2013).
//